Detalhe da pesquisa
1.
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
Oncologist
; 29(3): 254-262, 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38262444
2.
Cost of care for malignant and benign renal masses.
Am J Manag Care
; 19(8): 617-24, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24304211